Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS

Acta Neuropathologica

Volumn 131, Issue 4, 2016, Pages 587-604

  Suárez Calvet, Marc ^a,d,g   Neumann, Manuela ^c,d   Arzberger, Thomas ^a,d,e   Abou Ajram, Claudia ^a,b   Funk, Eva ^a   Hartmann, Hannelore ^d,f   Edbauer, Dieter ^d,f   Kremmer, Elisabeth ^h   Göbl, Christoph ^h,i   Resch, Moritz ^h,i   Bourgeois, Benjamin ^h,i   Madl, Tobias ^h,i,j,k   Reber, Stefan ^l   Jutzi, Daniel ^l   Ruepp, Marc David ^l   Mackenzie, Ian R A ^m   Ansorge, Olaf ⁿ   Dormann, Dorothee ^a,b,f   Haass, Christian ^a,d,f  

^a UNIVERSITY OF MUNICH   (Germany)

^b Lehrstuhl Zellbiologie (Anatomie III)   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Munich Cluster for Systems Neurology ^*  (Germany)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k BIOTECHMED GRAZ   (Austria)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

Amyotrophic lateral sclerosis (ALS); Arginine methylation; Frontotemporal lobar degeneration (FTLD); Fused in sarcoma (FUS); Neurodegeneration; Protein arginine methyltransferase 1 (PRMT1); Transportin 1

Indexed keywords

ANTIBODY; ARGININE; CARRIER PROTEIN; CELL NUCLEUS DNA; FUSED IN SARCOMA PROTEIN; MONOCLONAL ANTIBODY; MONOMETHYLATED ARGININE; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE; TRANSPORTIN 1; UNCLASSIFIED DRUG; UNMETHYLATED ARGININE; ENZYME INHIBITOR; KARYOPHERIN BETA; PROTEIN BINDING; RNA BINDING PROTEIN FUS; TNPO1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DNA METHYLATION; EMBRYO; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MOUSE; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CELL INCLUSION; CYTOLOGY; DRUG EFFECTS; EMBRYONIC STEM CELL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; MAMMALIAN EMBRYO; METABOLISM; METHYLATION; NERVE CELL; RAT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODIES; ARGININE; BETA KARYOPHERINS; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; EMBRYONIC STEM CELLS; ENZYME INHIBITORS; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; INCLUSION BODIES; MALE; METHYLATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PROTEIN BINDING; PROTEIN-ARGININE N-METHYLTRANSFERASES; RATS; RNA-BINDING PROTEIN FUS;

EID: 84961231197     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1544-2     Document Type: Article

References (60)

1. Araya N, Hiraga H, Kako K, Arao Y, Kato S, Fukamizu A (2005) Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1. Biochem Biophys Res Commun 329:653–660. doi:10.1016/j.bbrc.2005.02.018
2. Bedford MT, Clarke SG (2009) Protein arginine methylation in mammals: who, what, and why. Mol Cell 33:1–13. doi:10.1016/j.molcel.2008.12.013
3. Belyanskaya LL, Delattre O, Gehring H (2003) Expression and subcellular localization of Ewing sarcoma (EWS) protein is affected by the methylation process. Exp Cell Res 288:374–381
4. Belyanskaya LL, Gehrig PM, Gehring H (2001) Exposure on cell surface and extensive arginine methylation of Ewing Sarcoma (EWS) protein. J Biol Chem 276:18681–18687. doi:10.1074/jbc.M011446200
5. Brelstaff J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R, Revesz T (2011) Transportin1: a marker of FTLD-FUS. Acta Neuropathol 122:591–600. doi:10.1007/s00401-011-0863-6
6. Chen DH, Wu KT, Hung CJ, Hsieh M, Li C (2004) Effects of adenosine dialdehyde treatment on in vitro and in vivo stable protein methylation in HeLa cells. J Biochem 136:371–376. doi:10.1093/jb/mvh131
7. Chook YM, Süel KE (2011) Nuclear import by karyopherin-βs: recognition and inhibition. Biochim Biophys Acta 1813:1593–1606. doi:10.1016/j.bbamcr.2010.10.014
8. Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, Ito D, Murray ME, Dickson DW, Seyfried NT, Kukar T (2014) FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci 34:7802–7813. doi:10.1523/jneurosci.0172-14.2014
9. Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo A, Richard S, Comb MJ, Guo A, Clarke SG, Bedford MT (2013) Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci Rep 3:1311. doi:10.1038/srep01311
10. Dickson DW (2001) Neuropathology of Pick’s disease. Neurology 56:S16–S20
11. Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, Kremmer E, Matsuwaki T, Yamanouchi K, Nishihara M, Haass C (2009) Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem 110:1082–1094. doi:10.1111/j.1471-4159.2009.06211.x
12. Dormann D, Haass C (2013) Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. Mol Cell Neurosci 56:475–486. doi:10.1016/j.mcn.2013.03.006
13. Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, Kremmer E, Ansorge O, Mackenzie IR, Neumann M, Haass C (2012) Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J 31:4258–4275. doi:10.1038/emboj.2012.261
14. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, Neumann M, Haass C (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 29:2841–2857. doi:10.1038/emboj.2010.143
15. Gardiner M, Toth R, Vandermoere F, Morrice NA, Rouse J (2008) Identification and characterization of FUS/TLS as a new target of ATM. Biochem J 415:297–307. doi:10.1042/BJ20081135
16. Guo A, Gu H, Zhou J, Mulhern D, Wang Y, Lee KA, Yang V, Aguiar M, Kornhauser J, Jia X, Ren J, Beausoleil SA, Silva JC, Vemulapalli V, Bedford MT, Comb MJ (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13:372–387. doi:10.1074/mcp.O113.027870
17. Holm IE, Englund E, Mackenzie IR, Johannsen P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66:884–891. doi:10.1097/nen.0b013e3181567f02
18. Holm IE, Isaacs AM, Mackenzie IR (2009) Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol 118:719–720. doi:10.1007/s00401-009-0593-1
19. Hung CJ, Lee YJ, Chen DH, Li C (2009) Proteomic analysis of methylarginine-containing proteins in HeLa cells by two-dimensional gel electrophoresis and immunoblotting with a methylarginine-specific antibody. Protein J 28:139–147. doi:10.1007/s10930-009-9174-3
20. Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N (2011) Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann Neurol 69:152–162. doi:10.1002/ana.22246
21. Jobert L, Argentini M, Tora L (2009) PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. Exp Cell Res 315:1273–1286. doi:10.1016/j.yexcr.2008.12.008
22. Kino Y, Washizu C, Aquilanti E, Okuno M, Kurosawa M, Yamada M, Doi H, Nukina N (2011) Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic Acids Res 39:2781–2798. doi:10.1093/nar/gkq1162
23. Klevernic IV, Morton S, Davis RJ, Cohen P (2009) Phosphorylation of Ewing’s sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 418:625–634. doi:10.1042/BJ20082097
24. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208. doi:10.1126/science.1166066
25. Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, Van den Broeck M, Mattheijssens M, Peeters K, De Deyn PP, Cruts M, Van Broeckhoven C (2010) Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74:366–371. doi:10.1212/WNL.0b013e3181ccc732
26. Lee HJ, Kim S, Pelletier J, Kim J (2004) Stimulation of hTAFII68 (NTD)-mediated transactivation by v-Src. FEBS Lett 564:188–198. doi:10.1016/S0014-5793(04)00314-X
27. Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J, Lee M, Chung CH, Seo SB, Yoon JB, Ko E, Noh DY, Kim KI, Kim KK, Baek SH (2012) EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell 48:572–586. doi:10.1016/j.molcel.2012.09.004
28. Leemann-Zakaryan RP, Pahlich S, Grossenbacher D, Gehring H (2011) Tyrosine phosphorylation in the C-terminal nuclear localization and retention signal (C-NLS) of the EWS protein. Sarcoma 2011:218483. doi:10.1155/2011/218483
29. Liu Q, Dreyfuss G (1995) In vivo and in vitro arginine methylation of RNA-binding proteins. Mol Cell Biol 15:2800–2808
30. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4. doi:10.1007/s00401-009-0612-2
31. Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9:995–1007. doi:10.1016/S1474-4422(10)70195-2
32. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:617–627. doi:10.1007/s00401-009-0598-9
33. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554
34. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ang LC, Bilbao J, Rademakers R, Haass C, Mackenzie IR (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:2595–2609. doi:10.1093/brain/awr201
35. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931. doi:10.1093/brain/awp214
36. Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616. doi:10.1007/s00401-009-0581-5
37. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi:10.1126/science.1134108
38. Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IR (2012) Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol 124:705–716. doi:10.1007/s00401-012-1020-6
39. Niu C, Zhang J, Gao F, Yang L, Jia M, Zhu H, Gong W (2012) FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS One 7:e47056. doi:10.1371/journal.pone.0047056
40. Ong SE, Mittler G, Mann M (2004) Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 1:119–126. doi:10.1038/nmeth715
41. Orozco D, Tahirovic S, Rentzsch K, Schwenk BM, Haass C, Edbauer D (2012) Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep 13:759–764. doi:10.1038/embor.2012.90
42. Ostareck-Lederer A, Ostareck DH, Rucknagel KP, Schierhorn A, Moritz B, Huttelmaier S, Flach N, Handoko L, Wahle E (2006) Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src. J Biol Chem 281:11115–11125. doi:10.1074/jbc.M513053200
43. Pahlich S, Bschir K, Chiavi C, Belyanskaya L, Gehring H (2005) Different methylation characteristics of protein arginine methyltransferase 1 and 3 toward the Ewing Sarcoma protein and a peptide. Proteins 61:164–175. doi:10.1002/prot.20579
44. Pawlak MR, Scherer CA, Chen J, Roshon MJ, Ruley HE (2000) Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol Cell Biol 20:4859–4869. doi:10.1128/MCB.20.13.4859-4869.2000
45. Perreault A, Lemieux C, Bachand F (2007) Regulation of the nuclear poly(A)-binding protein by arginine methylation in fission yeast. J Biol Chem 282:7552–7562. doi:10.1074/jbc.M610512200
46. Rappsilber J, Friesen WJ, Paushkin S, Dreyfuss G, Mann M (2003) Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal Chem 75:3107–3114
47. Ravenscroft TA, Baker MC, Rutherford NJ, Neumann M, Mackenzie IR, Josephs KA, Boeve BF, Petersen R, Halliday GM, Kril J, van Swieten JC, Seeley WW, Dickson DW, Rademakers R (2013) Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiol Aging 34:2235.e11–2235.e13. doi:10.1016/j.neurobiolaging.2013.04.004
48. Sylvestersen KB, Horn H, Jungmichel S, Jensen LJ, Nielsen ML (2014) Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest. Mol Cell Proteomics 13:2072–2088. doi:10.1074/mcp.O113.032748
49. Talbot K, Ansorge O (2006) Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet 15:R182–R187. doi:10.1093/hmg/ddl202
50. Tang J, Frankel A, Cook RJ, Kim S, Paik K, Williams KR, Clarke S, Herschman HR (2000) PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 275:7723–7730
51. Thandapani P, O’Connor TR, Bailey TL, Richard S (2013) Defining the RGG/RG motif. Mol Cell 50:613–623. doi:10.1016/j.molcel.2013.05.021
52. Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S (2012) Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet 21:136–149. doi:10.1093/hmg/ddr448
53. Troakes C, Hortobágyi T, Vance C, Al-Sarraj S, Rogelj B, Shaw CE (2013) Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusi. Neuropathol Appl Neurobiol 39:553–561. doi:10.1111/j.1365-2990.2012.01300.x
54. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211. doi:10.1126/science.1165942
55. Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, Urwin H, Manser C, Miller CC, Hortobágyi T, Dragunow M, Rogelj B, Shaw CE (2013) ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet 22:2676–2688. doi:10.1093/hmg/ddt117
56. Yamaguchi A, Kitajo K (2012) The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS. PLoS One 7:e49267. doi:10.1371/journal.pone.0049267
57. Yang Y, Bedford MT (2013) Protein arginine methyltransferases and cancer. Nat Rev Cancer 13:37–50. doi:10.1038/nrc3409
58. Yu MC, Bachand F, McBride AE, Komili S, Casolari JM, Silver PA (2004) Arginine methyltransferase affects interactions and recruitment of mRNA processing and export factors. Genes Dev 18:2024–2035. doi:10.1101/gad.1223204
59. Zhang ZC, Chook YM (2012) Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). Proc Natl Acad Sci 109:12017–12021. doi:10.1073/pnas.1207247109
60. Zurita-Lopez CI, Sandberg T, Kelly R, Clarke SG (2012) Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues. J Biol Chem 287:7859–7870. doi:10.1074/jbc.M111.336271